Latest Breaking News On - மாற்ற பார்மா - Page 1 : comparemela.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Hyloris Reports 2021 Half-Year Results: Multiple Potential Value Inflection Points Ahead Hyloris Pharmaceuticals SAAugust 4, 2021 GMT  On target to grow the broad product pipeline with at least 3 additional programmes before end 2021 Significant expansion of commercial footprint of non-opioid pain treatment Maxigesic® IV Expected to start 2 clinical studies and to report the results from 2 clinical studies before year-end €53.47 million in cash and cash equivalents to execute ambitious growth strategy Conference call and webcast today at 3pm CEST/9am EST (details below) Liège, Belgium – 4 August 2021 – Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today reports its condensed consolidated financial results for the six-month period ending 30 June 2021,

United statesUnited kingdomMarieke vermeerschStijn van rompayMiconazole domiphenOlivier declercqChris buyseAlter pharma group for maxigesicAlter pharma groupInternational standard on review engagementsHyloris pharmaceuticalsCompany group structureHyloris pharmaceuticals sa euronext brusselsCorporate communicationsPharma bavaria internationalHikma pharmaceuticals